& Kowarski, A
In a randomized trial using PET-MRI to assess carotid plaque inflammation, semaglutide did not show a significant difference versus placebo on the prespecified primary plaque-inflammation endpointslikely influenced by low baseline inflammatory burden in a well-treated population. How to interpret this: Imaging studies like this are helpful for understanding mechanisms and terminology (e.g., atherosclerotic inflammation, PET-MRI plaque imaging), but they do not establish semaglutide as a direct vascular inflammation imaging reducer in general clinical use based on current evidence. 5) They Improve Kidney Outcomes in High-Risk Populations (Semaglutide) By improving glycemic control and metabolic stress, GLP-1 therapies can reduce kidney risk in susceptible patients
This regulatory development is highly relevant to industry as it signals a shift toward more integrated and technology-driven weight management approaches and chronic disease prevention strategies In this space, Kelker Pharma recently introduced Nutrilinq Genesis, touted as the first science-backed nutritional support system for GLP-1 therapy patients
J Anim Sci 38 : 9971002
Take the Next Step Toward a Healthier You Schedule your weight loss consultation at Magnifique Medical Spa in Pleasant Grove, Utah today to discover whether Semaglutide or Tirzepatide is the right fit for your goals
Cardiovascular outcome trials (CVOTs) of GLP-1RAs To date, the REWIND study has demonstrated for the first time that primary cardiovascular prevention strategies can significantly reduce cardiovascular adverse events in patients with T2DM, regardless of whether or not these patients are co-diagnosed with CVD [23]
